Biopharmaceutical and drug discovery platform company PeptiDream (TSE:4587, Financial) was a detractor from performance for the quarter. While the company continues to collaborate with drug makers and licenses its drug discovery technologies the underperformance was mostly from multiple contraction from a very high range.
From Matthews Japan Fund (Trades, Portfolio)'s first-quarter 2020 commentary.